About GSK
Funding & Growth
✓ Pros
- • Strong vaccines and specialty pharma portfolio
- • Heavy investment in AI/ML for drug discovery
- • Global presence with US hubs
- • Good work-life balance
- • Partnerships with 23andMe, AI companies
✗ Cons
- • Recent spin-off (Haleon) transition
- • UK headquarters (timezone challenges)
- • Large company bureaucracy
- • Restructuring in some areas
🏢 Working Here
GSK operates computational biology across multiple US sites including collaborations in Cambridge/Boston, MA (for genetics and discovery research), Philadelphia, PA, and Collegeville, PA (post-split headquarters), alongside a major presence in Stevenage, UK.
Following the 2022 separation creating GSK (biopharma) and Haleon (consumer health), the company focuses on infectious diseases, HIV, oncology, and immunology.
GSK maintains strong Boston-area connections through partnerships with academic institutions and positioning scientists near the Broad Institute and other genetics powerhouses - critical for their human genetics-driven drug discovery strategy.
The company has pioneered functional genomics with genome-wide CRISPR screens and maintains one of pharma's largest AI efforts through partnerships with Exscientia and Insilico Medicine.
Bioinformaticians work on diverse programs: Shingrix (shingles vaccine), HIV antivirals (Dovato, Cabenuva), RSV vaccine, and oncology (zejula PARP inhibitor).
The culture values scientific rigor, innovation, and genetic validation of targets.
Work involves integrating population-scale genetics with CRISPR screens, infectious disease surveillance, and AI-driven drug discovery.
GSK's multi-site structure allows scientists to be where their expertise is most valuable - Boston area for genetics collaborations, Pennsylvania for clinical development, UK for core research.
🧬 Bioinformatics Focus
GSK's computational biology emphasizes genetics-driven drug discovery and infectious diseases. Core areas:
- Human genetics at scale - analyzing UK Biobank (500K genomes), FinnGen, and proprietary cohorts for target validation, pioneering statistical methods for rare variant analysis,
- Functional genomics - genome-wide CRISPR screens in disease-relevant cell types, analyzing genetic perturbation data to identify drug targets,
- AI for drug discovery - partnerships with Exscientia (AI-designed small molecules), Insilico Medicine (generative chemistry), using ML for compound property prediction,
- Infectious disease genomics - pathogen sequencing for vaccine design (RSV, HIV, malaria), surveillance for antimicrobial resistance, host-pathogen interaction modeling,
- Cancer genomics - analyzing genetic dependencies in cancer using CRISPR screens, biomarkers for PARP inhibitors and other oncology programs. GSK has published extensively on systematic target validation using genetics (23andMe collaboration, UK Biobank analyses). Technical challenges include integrating genetics with functional evidence, designing AI models that work prospectively (not just retrospectively), and analyzing complex host-pathogen interactions.
📈 Career Growth & Development
Career Paths
Scientist Track
Management Track
Compensation
Competitive US salaries with 12-18% target bonuses and stock options. The Philadelphia/Collegeville area offers a lower cost of living than Boston/SF.
Development
GSK emphasizes continuous learning through extensive training programs. They encourage external collaborations and publications.
Mobility
Internal mobility between therapeutic areas and US/UK sites is supported. Some roles may require UK work authorization.
Network
GSK's alumni network is global given its size. The 2022 company split created reorganization but also new opportunities.
Culture
GSK's commitment to AI/ML creates opportunities to work at the cutting edge. The focused biopharma strategy post-split positions GSK well for long-term success.
Expertise
Many GSK computational biologists specialize in genetics, functional genomics, or infectious diseases. The company's commitment to AI/ML creates opportunities to work at the cutting edge.
💊 Top Medicines & Blockbuster Drugs
Shingrix
2017Indication: Shingles (herpes zoster) vaccine
Recombinant zoster vaccine - 90%+ efficacy, 94% market share
Annual Revenue (USD)
Trelegy Ellipta
2017Indication: COPD and asthma - triple therapy inhaler
Fluticasone/umeclidinium/vilanterol combination
Annual Revenue (USD)
Nucala (mepolizumab)
2015Indication: Severe eosinophilic asthma, EGPA, hypereosinophilic syndrome
IL-5 inhibitor
Annual Revenue (USD)
Zejula (niraparib)
2017Indication: Ovarian cancer - PARP inhibitor
Maintenance therapy post-chemotherapy
Annual Revenue (USD)
Blenrep (belantamab mafodotin)
2020Indication: Relapsed/refractory multiple myeloma
BCMA-targeted antibody-drug conjugate
Annual Revenue (USD)